{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T20:48:20Z","timestamp":1769201300935,"version":"3.49.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To compare the recurrence rate of retinopathy of prematurity (ROP) after treatment with 0.3\u2009mg vs. 0.25\u2009mg ranibizumab.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Subjects<\/jats:title>\n                <jats:p>All patients with ROP who underwent intravitreal injection of ranibizumab in Hainan General Hospital between January 2014 and May 2020 were included in this retrospective study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Eighty-two cases (146 eyes) who received intravitreal injection of 0.25\u2009mg ranibizumab were included in the conventional-dose group, and 59 cases (108 eyes) who received intravitreal injection of 0.3\u2009mg ranibizumab were included in the high-dose group. The two groups were further divided into the 25-28-week, 29-31-week, 32-34-week, and 35-36-week GA subgroups. The differences between the conventional-dose group and the high-dose group in gestational age (GA), birth weight (BW), age at initial injection (weeks), incidence of systemic diseases, the recurrence rate of ROP, and age at retinal vascularization completed (weeks) were analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>GA, BW, age at initial injection, and the incidence of systemic diseases were not significantly different between the conventional-dose group and the high-dose group (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). The recurrence rates of ROP were significantly lower in the 25-28-week, 29-31-week, and 32-34-week subgroups of the high-dose group than in the same subgroups of the conventional-dose group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Within the conventional-dose group, the recurrence rate of ROP was significantly lower in the 32-34-week and 35-36-week subgroups than in the 25-28-week and 29-31-week subgroups (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Within the high-dose group, the recurrence rate of ROP was not significantly different between the four subgroups (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). Retinal vascularization was completed at a later age in the 32-34-week subgroup of the high-dose group than in the 32-34-week subgroup of the conventional-dose group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) but was not significantly different between the two groups at any other GA range (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). No severe ocular or systemic complications occurred in any patient.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Treatment with 0.3\u2009mg ranibizumab can reduce the recurrence rate of ROP without prolonging retinal vascularization or causing serious systemic complications. Therefore, this dose may be an appropriate therapeutic dose for ROP.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-022-02489-6","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T09:03:11Z","timestamp":1655802191000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Appropriate dose of intravitreal ranibizumab for ROP: a retrospective study"],"prefix":"10.1186","volume":"22","author":[{"given":"Yingying","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaoli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingyue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizhen","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qionglei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,21]]},"reference":[{"key":"2489_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0002-9394(42)92088-9","volume":"25","author":"TL Terry","year":"1942","unstructured":"Terry TL. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline Lens: I. Preliminary report. Am J Ophthalmol. 1942;25:203\u20134.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"2489_CR2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/aos.13549","volume":"96","author":"G Holmstr\u00f6m","year":"2018","unstructured":"Holmstr\u00f6m G, Tornqvist K, Al-Hawasi A, et al. Increased frequency of retinopathy of prematurity over the last decade and significant regional differences. Acta Ophthalmol. 2018;96(2):142\u20138.","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"2489_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jaapos.2015.02.012","volume":"19","author":"S Chamney","year":"2015","unstructured":"Chamney S, McGrory L, McCall E, et al. Treatment of retinopathy of prematurity in Northern Ireland, 2000-2011: a population-based study. J AAPOS. 2015;19(3):223\u20137.","journal-title":"J AAPOS"},{"issue":"1","key":"2489_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3233\/NPM-915142","volume":"10","author":"J Edy Siswanto","year":"2017","unstructured":"Edy Siswanto J, Sauer PJ. Retinopathy of prematurity in Indonesia: incidence and risk factors. J Neonatal Perinatal Med. 2017;10(1):85\u201390.","journal-title":"J Neonatal Perinatal Med"},{"issue":"9902","key":"2489_CR5","doi-asserted-by":"publisher","first-page":"1445 1457","DOI":"10.1016\/S0140-6736(13)60178-6","volume":"382","author":"A Hellstr\u00f6m","year":"2013","unstructured":"Hellstr\u00f6m A, Smith LE, Dammann O. Retinopathy of prematurity [J]. Lancet. 2013;382(9902):1445 1457.","journal-title":"Lancet"},{"issue":"12","key":"2489_CR6","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.earlhumdev.2012.09.019","volume":"88","author":"HA Mintz-Hittner","year":"2012","unstructured":"Mintz-Hittner HA. Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitor. Early Hum Dev. 2012;88(12):937\u201341.","journal-title":"Early Hum Dev"},{"issue":"7","key":"2489_CR7","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","volume":"123","author":"International Committee for the Classification of Retinopathy of Prematurity (2005)","year":"2005","unstructured":"International Committee for the Classification of Retinopathy of Prematurity (2005). The international classification of retinopathy of prematurity revisited [J]. Arch Ophthalmol. 2005;123(7):991\u20139.","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"2489_CR8","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment For Retinopathy Of Prematurity Cooperative Group","year":"2003","unstructured":"Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121(12):1684\u201394.","journal-title":"Arch Ophthalmol"},{"key":"2489_CR9","first-page":"233","volume":"102","author":"WV Good","year":"2004","unstructured":"Good WV. Early treatment for retinopathy of prematurity cooperative group. Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233\u201348.","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"12","key":"2489_CR10","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1007\/s12098-017-2404-3","volume":"84","author":"MR Dogra","year":"2017","unstructured":"Dogra MR, Katoch D, Dogra M. An update on retinopathy of prematurity (ROP). Indian J Pediatr. 2017;84(12):930\u20136.","journal-title":"Indian J Pediatr"},{"key":"2489_CR11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ajo.2012.06.010","volume":"155","author":"WC Wu","year":"2013","unstructured":"Wu WC, Kuo HK, Yeh PT, et al. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan. Am J Ophthalmol. 2013;155:150\u20138.","journal-title":"Am J Ophthalmol"},{"key":"2489_CR12","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","volume":"98","author":"SG Tahija","year":"2014","unstructured":"Tahija SG, Hersetyati R, Lam GC, et al. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. Br J Ophthalmol. 2014;98:507\u201312.","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"2489_CR13","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","volume":"245","author":"EJ Chung","year":"2007","unstructured":"Chung EJ, Kim JH, Ahn HS, Koh HJ. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone 1 retinopathy of prematurity. Grafes Arch Clin Exp Ophthalmol. 2007;245(11):1727\u201330.","journal-title":"Grafes Arch Clin Exp Ophthalmol."},{"issue":"3","key":"2489_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3928\/15428877-20070501-09","volume":"38","author":"A Travassos","year":"2007","unstructured":"Travassos A, Teixeria S, Ferreira P, Regadas I, Travassos AS, Esperancinha FE, et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging. 2007;38(3):233\u20137.","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"6","key":"2489_CR15","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1089\/jop.2011.0060","volume":"27","author":"BC Harder","year":"2011","unstructured":"Harder BC, Baltz SV, Jonas JB, Schlichtenbrede FC. Intravitreal bevacizumab for retinopathy of prematurity. J Ocul Pharmacol Ther. 2011;27(6):623\u20137.","journal-title":"J Ocul Pharmacol Ther"},{"key":"2489_CR16","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","volume":"122","author":"CK Hwang","year":"2015","unstructured":"Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology. 2015;122:1008\u201315.","journal-title":"Ophthalmology"},{"key":"2489_CR17","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","volume":"121","author":"D Lepore","year":"2014","unstructured":"Lepore D, Quinn GE, Molle F, et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology. 2014;121:2212\u20139.","journal-title":"Ophthalmology"},{"issue":"7","key":"2489_CR18","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603\u201315.","journal-title":"N Engl J Med"},{"issue":"3","key":"2489_CR19","first-page":"207","volume":"79","author":"LP Orozco-G\u00f3mez","year":"2011","unstructured":"Orozco-G\u00f3mez LP, Hern\u00e1ndez-Salazar L, Moguel-Ancheita S, et al. Laser-ranibizumab treatment for retinopathy of prematurity in umbral-preumbral disease. Three years of experience. Cir Cir May-Jun. 2011;79(3):207\u201314 225-32.","journal-title":"Cir Cir May-Jun"},{"key":"2489_CR20","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1136\/bjophthalmol-2012-302276","volume":"97","author":"MA Castellanos","year":"2013","unstructured":"Castellanos MA, Schwartz S, Garc\u00eda-Aguirre G, QuirozMercado H. Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Br J Ophthalmol. 2013;97:816\u20139.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"2489_CR21","first-page":"28","volume":"30","author":"Y Xu","year":"2014","unstructured":"Xu Y, Qi Z, Xunda J, et al. Efficacy of intravitreal injection of anti VEGF monoclonal antibody ranibizumab combined with laser photocoagulation in the treatment of rapidly progressive posterior retinopathy of prematurity. Chin J Ocul Fundus Dis. 2014;30(1):28\u201332.","journal-title":"Chin J Ocul Fundus Dis"},{"issue":"6","key":"2489_CR22","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","volume":"135","author":"DK Wallace","year":"2017","unstructured":"Wallace DK, Kraker RT, Freedman SF, et al. Assessment of lower doses of Intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study. JAMA Ophthalmol. 2017;135(6):654\u20136.","journal-title":"JAMA Ophthalmol"},{"issue":"10208","key":"2489_CR23","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","volume":"394","author":"A Stahl","year":"2019","unstructured":"Stahl A, Lepore D, Fielder A, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet. 2019;394(10208):1551\u20139.","journal-title":"Lancet."},{"issue":"4","key":"2489_CR24","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","volume":"35","author":"S-N Chen","year":"2015","unstructured":"Chen S-N, Lian I, Hwang Y-C, et al. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and bevacizumab. Retina. 2015;35(4):667\u201374.","journal-title":"Retina."},{"key":"2489_CR25","first-page":"340","volume":"78","author":"MK Erol","year":"2015","unstructured":"Erol MK, et al. Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity. Arq Bras Oftalmol. 2015;78:340\u20133.","journal-title":"Arq Bras Oftalmol"},{"issue":"4","key":"2489_CR26","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","volume":"35","author":"RK Wong","year":"2015","unstructured":"Wong RK, Hubschman S, Tsui I. Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina. 2015;35(4):675\u201380.","journal-title":"Retina."},{"key":"2489_CR27","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1159\/000338623","volume":"3","author":"A Mota","year":"2012","unstructured":"Mota A, et al. Combination of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity. Case Rep Ophthalmol. 2012;3:136\u201341.","journal-title":"Case Rep Ophthalmol"},{"issue":"5 Suppl","key":"2489_CR28","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/00006982-200410001-00002","volume":"24","author":"LP Aiello","year":"2004","unstructured":"Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina. 2004;24(5 Suppl):S3\u201319.","journal-title":"Retina."},{"issue":"1","key":"2489_CR29","first-page":"76","volume":"49","author":"Cataract and intraocular lens group, ophthalmology branch, Chinese Medical Association","year":"2013","unstructured":"Cataract and intraocular lens group, ophthalmology branch, Chinese Medical Association. Expert advice on standardization of infection prevention measures during cataract surgery (2013) [J]. Chin J Ophthalmol. 2013;49(1):76\u20138.","journal-title":"Chin J Ophthalmol"},{"issue":"7","key":"2489_CR30","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.18240\/ijo.2019.07.15","volume":"12","author":"Q-Y Meng","year":"2019","unstructured":"Meng Q-Y, Cheng Y, Zhao M-W, et al. The process of retinal vascularization in retinopathy of prematurity after ranibizumab treatment in China. Int J Ophthalmol. 2019;12(7):1146\u201350.","journal-title":"Int J Ophthalmol"},{"key":"2489_CR31","doi-asserted-by":"publisher","first-page":"27082","DOI":"10.1038\/srep27082","volume":"6","author":"JJT Chan","year":"2016","unstructured":"Chan JJT, Lam CPS, Kwok MKM, et al. Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy. Sci Rep. 2016;6:27082.","journal-title":"Sci Rep"},{"issue":"9902","key":"2489_CR32","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","volume":"382","author":"A Hellstr\u00f6m","year":"2013","unstructured":"Hellstr\u00f6m A, Smith LEH, Dammann O. Retinopathy of prematurity. Lancet. 2013;382(9902):1445\u201357.","journal-title":"Lancet."},{"key":"2489_CR33","doi-asserted-by":"publisher","first-page":"e1483","DOI":"10.1542\/peds.2009-2218","volume":"125","author":"ML Chen","year":"2010","unstructured":"Chen ML, Guo L, Smith LE, Dammann CE, Dammann O. High or low oxygen saturation and severe retinopathy of prematurity: a meta-analysis. Pediatrics. 2010;125:e1483\u201392.","journal-title":"Pediatrics."},{"key":"2489_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1471-2431-5-18","volume":"5","author":"P Karna","year":"2005","unstructured":"Karna P, Muttineni J, Angell L, Karmaus W. Retinopathy of prematurity and risk factors: a prospective cohort study. BMC Pediatr. 2005;5:18.","journal-title":"BMC Pediatr"},{"issue":"12","key":"2489_CR35","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1111\/j.1651-2227.2011.02445.x","volume":"100","author":"AL H\u00e5rd","year":"2011","unstructured":"H\u00e5rd AL, Hellstr\u00f6m A. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment: a review. Acta Paediatr. 2011;100(12):1523\u20137.","journal-title":"Acta Paediatr"},{"key":"2489_CR36","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nm721","volume":"8","author":"V Compernolle","year":"2002","unstructured":"Compernolle V, Brusselmans K, Acker T, et al. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med. 2002;8:702\u201310.","journal-title":"Nat Med"},{"issue":"1","key":"2489_CR37","first-page":"56","volume":"7","author":"KD Tran","year":"2018","unstructured":"Tran KD, Cernichiaro-Espinosa LA, Berrocal AM. Management of Retinopathy of Prematurity--Use of Anti-VEGF Therapy. Asia Pac J Ophthalmol (Phila). 2018;7(1):56\u201362.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"2","key":"2489_CR38","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/MOP.0b013e3283423f35","volume":"23","author":"J Chen","year":"2011","unstructured":"Chen J, Stahl A, Hellstrom A, Smith LE. Current update on retinopathy of prematurity: screening and treatment. Curr Opin Pediatr. 2011;23(2):173\u20138.","journal-title":"Curr Opin Pediatr"},{"issue":"7","key":"2489_CR39","doi-asserted-by":"publisher","first-page":"e70513","DOI":"10.1371\/journal.pone.0070513","volume":"8","author":"BV Bui","year":"2013","unstructured":"Bang V Bui , Abrez H Batcha, Erica Fletcher, , et al. Relationship between the magnitude of intraocular pressure during an episode of acute elevation and retinal damage four weeks later in rats [J]. PLoS One. 2013;8(7):e70513.","journal-title":"PLoS One"},{"key":"2489_CR40","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1159\/000369478","volume":"233","author":"V Lemos","year":"2015","unstructured":"Lemos V, Cabugueira A, Noronha M, et al. Intraocular pressure in eyes receiving intravitreal antivascular endothelial growth factor injections. Ophthalmologica. 2015;233:162\u20138.","journal-title":"Ophthalmologica"},{"issue":"10 Suppl","key":"2489_CR41","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.ophtha.2009.06.045","volume":"116","author":"SB Bressler","year":"2009","unstructured":"Bressler SB. Introduction: understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology. 2009;116(10 Suppl):S1\u20137.","journal-title":"Ophthalmology"},{"key":"2489_CR42","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","volume":"98","author":"RL Avery","year":"2014","unstructured":"Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014;98:1636\u201341.","journal-title":"Br J Ophthalmol"},{"key":"2489_CR43","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1136\/bjophthalmol-2012-302451","volume":"97","author":"C Zehetner","year":"2013","unstructured":"Zehetner C, Kirchmair R, Huber S, et al. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol. 2013;97:454\u20139.","journal-title":"Br J Ophthalmol"},{"key":"2489_CR44","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1111\/j.1755-3768.2011.02240.x","volume":"90","author":"AM Carneiro","year":"2012","unstructured":"Carneiro AM, Costa R, Falcao MS, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol. 2012;90:e25\u201330.","journal-title":"Acta Ophthalmol"},{"key":"2489_CR45","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1111\/j.1755-3768.2012.02469.x","volume":"91","author":"R Hoerster","year":"2013","unstructured":"Hoerster R, Muether P, Dahlke C, et al. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol. 2013;91:e74\u20135.","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"2489_CR46","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1111\/j.1755-3768.2012.02552.x","volume":"91","author":"U Spandau","year":"2013","unstructured":"Spandau U. What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity? Acta Ophthalmol. 2013 Mar;91(2):e154.","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"2489_CR47","doi-asserted-by":"publisher","first-page":"e475","DOI":"10.1111\/aos.13004","volume":"96","author":"J Han","year":"2018","unstructured":"Han J, Kim SE, Lee SC, et al. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison. Acta Ophthalmol. 2018;96(4):e475\u20138.","journal-title":"Acta Ophthalmol"},{"key":"2489_CR48","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.3928\/01913913-20150421-11","volume":"52","author":"AJ Connor","year":"2015","unstructured":"Connor AJ, Papastavrou VT, Hillier RJ, Shafiq A. Ultra-low dose of intravitreal bevacizumab in the treatment of retinopathy of prematurity. J Pediatric Ophthalmol Strabismus. 2015;52:e20\u20131.","journal-title":"J Pediatric Ophthalmol Strabismus"},{"issue":"7","key":"2489_CR49","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s00417-008-0786-7","volume":"246","author":"S Honda","year":"2008","unstructured":"Honda S, Hirabayashi H, Tsukahara Y, Negi A. Acute contraction of the membrane after intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Grafes Arch Clin Exp Ophthalmol. 2008;246(7):1061\u20133.","journal-title":"Grafes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"2489_CR50","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/eye.2009.156","volume":"24","author":"LC Zepeda-Romero","year":"2010","unstructured":"Zepeda-Romero LC, Liera-Garcia JA, Guti\u00e9rrez-Padilla JA, Valtierra-Santiago JI, Cardenas-Lamas LJ. Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity. Eye (Lond). 2010;24(5):931\u20133.","journal-title":"Eye (Lond)"},{"issue":"2","key":"2489_CR51","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.survophthal.2010.08.006","volume":"56","author":"M Tolentino","year":"2011","unstructured":"Tolentino M. Systemic and ocular safety of intravitreal anti-VEG F therapies for ocular neovascular disease. Surv Ophthalmol. 2011;56(2):95\u2013113.","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"2489_CR52","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jaapos.2011.11.002","volume":"16","author":"RL Avery","year":"2012","unstructured":"Avery RL. Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both? J AAPOS. 2012;16(1):2\u20134.","journal-title":"J AAPOS"},{"issue":"2","key":"2489_CR53","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/oxfordjournals.bmb.a070758","volume":"26","author":"N Ashton","year":"1970","unstructured":"Ashton N. Retinal angiogenesis in the human embryo. Br Med Bull. 1970;26(2):103\u20136.","journal-title":"Br Med Bull"},{"issue":"6","key":"2489_CR54","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1111\/aos.13008","volume":"94","author":"R Karkhaneh","year":"2016","unstructured":"Karkhaneh R, Khodabande A, Riazi-Eafahani M, Roohipoor R, Ghassemi F, Imani M, et al. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity. Acta Ophthalmol. 2016;94(6):e417\u201320.","journal-title":"Acta Ophthalmol"},{"key":"2489_CR55","first-page":"295","volume":"41","author":"H Yin","year":"2005","unstructured":"Yin H, Li XX, Li HL, Zhang W. Incidence and risk factor analysis of retinopathy of prematurity. Zhonghua Yan KeZa Zhi. 2005;41:295\u20139.","journal-title":"Zhonghua Yan KeZa Zhi"},{"key":"2489_CR56","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s13312-015-0594-1","volume":"52","author":"MP Chattopadhyay","year":"2015","unstructured":"Chattopadhyay MP, Pradhan A, Singh R, Datta S. Incidence and risk factors for retinopathy of prematurity in neonates. Indian Pediatr. 2015;52:157.","journal-title":"Indian Pediatr"},{"issue":"1","key":"2489_CR57","doi-asserted-by":"publisher","first-page":"12","DOI":"10.5935\/0004-2749.20180005","volume":"81","author":"S Dikci","year":"2018","unstructured":"Dikci S, Ceylan OM, Demirel S, Y\u0131lmaz T. Which dose of bevacizumab is more effective for the treatment of aggressive posterior retinopathy of prematurity: lower or higher dose? Arq Bras Oftalmol. 2018;81(1):12\u20137.","journal-title":"Arq Bras Oftalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02489-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-022-02489-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02489-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T10:09:44Z","timestamp":1655806184000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-022-02489-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2489"],"URL":"https:\/\/doi.org\/10.1186\/s12886-022-02489-6","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,21]]},"assertion":[{"value":"1 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Helsinki Declaration, it also was approved by the ethic committee of Hainan General Hospital and the consent from the patients\u2019 family members, the researchers provided sufficient information and guarantee of participation. All patients\u2019 families were fully aware of our purpose and method of this study, they had the right to reject the new dose without any reason. The privacy of the study participants must be protected and all participants were anonymous. Written informed consent was obtained from all patients\u2019 family members.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"271"}}